Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

other comprehensive income related to the recovery of fair value for four of the securities.

The net decrease in cash and short-term investments of $2.7 million was principally due to cash spent for operations and cash paid for principal and interest totaling $12.1 million related to the retirement of $17.0 million of convertible debt, which were partially offset by net proceeds from the sale of common stock to Cadila of $10.7 million and proceeds from the sale of stock under the ATM program of $14.0 million. Novavax believes that based on the balance of cash and short-term investments at June 30, 2009, along with the proceeds from its transaction with ROVI of $3.0 million and the proceeds of $8.0 million received from additional sales of stock under the ATM program in July 2009, it has sufficient funds to execute its current business plan for at least the next twelve months. Novavax may pursue additional funding through the potential sale of equity securities, other non-dilutive financing, or additional partnering agreements, as opportunities arise.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Conference Call

Novavax's management will host its quarterly conference call at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) today. The live conference call will be accessible via Novavax's website at www.novavax.com under Investor/Events or by tele
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... (PRWEB) October 17, 2014 ... offers a full line of Styrene-Butadiene polymer ... barrier coatings and a variety of other ... provide outstanding performance in these applications.  , ... in performance and cost effectiveness.  SB polymer ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The North ... concerned market in North America with analysis and forecast ... in 2013, and is expected to reach $1329.6 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. This also provides ...
(Date:10/17/2014)... Mediso stellt den MultiScan ... MultiScan-Produktreihe, das speziell für Forschungsanwendungen in der klinischen ... (Large Field of view Extreme Resolution) mit einem ... Sichtfeld in Breitenrichtung von 15 cm, einer PET-Auflösung ... % soll für die vorklinische Hirnforschung eingesetzt werden. ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 /PRNewswire/ ... - Research and Markets ( http://www.researchandmarkets.com/research/6cbkgn/latest_guidebook ) ... Guidebook for Conducting Medical Device Clinical Evaluation ... to Practices (2014 Edition)"  report to their ... , China,s regulatory framework ...
Breaking Biology Technology:Mallard Creek Polymers Reminds Industry of the Full Line of Styrene-Butadiene Polymer Emulsions 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 3Mediso enthüllt neues Forschungswerkzeug MultiScan LFER 150 PET/CT 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 3
... Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), ... tumor specific data to enhance the value of oncology drugs, today ... 2009. Full details of the Company,s financial results are available in ... , Total revenues for the first quarter of ...
... SINGAPORE, Sept. 14 China Agro-Technology Holdings (OTC ... website which is focused on spotlighting the company,s focus on ... website is located at www.chinaagrotech.com. , , ... Holdings Ltd., headquartered in Singapore, is focused on becoming a ...
... , , ... 14 Tobira Therapeutics Inc., a clinical stage biotechnology ... treatment of life-threatening and life-altering infectious diseases, today announced ... randomized study of TBR-652 in sixty healthy volunteers. ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 5Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2
... calls for policymakers to reduce both nitrogen and phosphorus ... problems in fresh and coastal waters. In the ... argue that dual-nutrient reduction strategies are likely to be ... phosphorus in fresh and coastal water ecosystems. "If ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... be exhausting. When fruit flies mate, the females, genes ... an immune reaction starts. This is shown in a ... the scientific publication, Journal of Evolutionary Biology .* ... genomic technology, so-called microarrays, researchers at Uppsala University can ...
Cached Biology News:Nutrient pollution chokes marine and freshwater ecosystems 2
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: